LNSR · LENSAR, Inc.
One customer — 14% of revenue (the three months ended March 31, 2026)
“For the three months ended March 31, 2026, one customer accounted for approximately 14% of our revenue.”
One customer — 12% of receivables (As of March 31, 2026)
“As of March 31, 2026, one customer accounted for approximately 12% of our accounts receivable, net.”
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $57.7M | $58.44M | $53.49M | $42.16M | $35.36M | $34.46M | $26.38M | $30.53M | |
| $6.58M | $6.78M | $7.53M | $6.45M | $5.92M | $4.97M | $3.6M | $4.18M | |
| $31.33M | $31.31M | $27.64M | $21.06M | $15.4M | $16.63M | $12.31M | $17.3M | |
| $26.38M | $27.12M | $25.85M | $21.11M | $19.96M | $17.83M | $14.08M | $13.23M | |
| — | 46.41% | 48.33% | 50.06% | 56.44% | 51.75% | 53.35% | 43.33% | |
| $5.47M | $5.62M | $5.33M | $6.14M | $11.81M | $12.36M | $7.55M | $7.57M | |
| $36.54M | $45.16M | $26.49M | $26.1M | $27.17M | $23.89M | $23.77M | $17.15M | |
| $918K | $921K | $970K | $1.1M | $1.15M | $1.24M | $1.26M | $1.23M | |
| -$16.55M | -$24.58M | -$10.67M | -$12.23M | -$20.18M | -$19.65M | -$18.5M | -$12.71M | |
| — | -42.06% | -19.94% | -29% | -57.06% | -57.03% | -70.13% | -41.65% | |
| — | — | — | — | — | — | $1.34M | $2M | |
| $622K | $636K | $660K | $698K | $263K | $51K | $68K | $58K | |
| — | -$34.28M | -$31.4M | -$14.38M | -$19.91M | -$19.6M | -$19.77M | -$14.66M | |
| $29.4M | -$34.28M | -$31.4M | -$14.38M | -$19.91M | -$19.6M | -$19.77M | -$14.66M | |
| — | -58.66% | -58.71% | -34.11% | -56.32% | -56.88% | -74.95% | -48.01% | |
| $29.39M | -$34.28M | -$31.4M | -$14.38M | -$19.91M | — | — | — | |
| USD/shares | — | -$2.87 | -$2.73 | -$1.31 | -$1.96 | -$2.09 | — | — |
| USD/shares | — | -$2.87 | -$2.73 | -$1.31 | -$1.96 | -$2.09 | — | — |
| shares | — | 11.96M | 11.52M | 10.97M | 10.16M | 9.37M | 4.62M | 1.07M |
| shares | — | 11.96M | 11.52M | 10.97M | 10.16M | 9.37M | 4.62M | 1.07M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 77 similar-size Medical Devices companies (of 145 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| United States | $34,313,000 | $28,907,000 | $25,262,000 | $18,776,000 | $15,004,000 | $11,604,000 |
| Europe | $8,427,000 | $10,157,000 | $5,585,000 | $4,409,000 | $5,805,000 | $3,588,000 |
| Asia Excluding South Korea | $8,020,000 | $5,487,000 | $3,836,000 | $3,576,000 | $3,855,000 | $4,193,000 |
| South Korea | $658,000 | $848,000 | $257,000 | $2,180,000 | $4,380,000 | $3,077,000 |
| Other Geographical Region | $238,000 | $563,000 | $776,000 | $502,000 | $449,000 | $319,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $45,928,000 | $41,065,000 | $31,643,000 | $25,959,000 | $26,246,000 | $19,831,000 |
| Service | $5,728,000 | $4,897,000 | $4,073,000 | $3,484,000 | $3,247,000 | $2,950,000 |